Adibelivir

• Description:

  Adibelivir (IM-250) is an orally active helicase-primase inhibitor. Adibelivir is effective against HSV infection and reduces reactivation of latent HSV. Adibelivir inhibits HSV-1 infection in Vero cells (IC50: ~20 nM) . Adibelivir can be used for the study of recurrent herpes disease[1][2].

• Product Name Alternative:

  IM-250

• UNSPSC:

  12352005

• Target:

  HSV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/im-250.html

• Purity:

  99.94

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  FC(C=CC(F)=C1)=C1C(C=C2)=CC=C2CC(N(C3=NC(C)=C([S@@](C)(=N)=O)S3)C)=O

• Molecular Formula:

  C20H19F2N3O2S2

• Molecular Weight:

  435.51

• References & Citations:

  [1]Bernstein DI, et al. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV. Antiviral Res. 2023 Nov;219:105733. |[2]Uhlig N, et al. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. 2021 Nov;195:105190.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [2305750-23-4]